Journal article

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

James W Denham, David Joseph, David S Lamb, Nigel A Spry, Gillian Duchesne, John Matthews, Chris Atkinson, Keen-Hun Tai, David Christie, Lizbeth Kenny, Sandra Turner, Nirdosh Kumar Gogna, Terry Diamond, Brett Delahunt, Chris Oldmeadow, John Attia, Allison Steigler

LANCET ONCOLOGY | ELSEVIER SCIENCE INC | Published : 2019

Abstract

BACKGROUND: The optimal duration of androgen suppression for men with locally advanced prostate cancer receiving radiotherapy with curative intent is yet to be defined. Zoledronic acid is effective in preventing androgen suppression-induced bone loss, but its role in preventing castration-sensitive bone metastases in locally advanced prostate cancer is unclear. The RADAR trial assessed whether the addition of 12 months of adjuvant androgen suppression, 18 months of zoledronic acid, or both, can improve outcomes in men with locally advanced prostate cancer who receive 6 months of androgen suppression and prostatic radiotherapy. This report presents 10-year outcomes from this trial. METHODS: F..

View full abstract